Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.
Standard
Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. / Köpke, S; Kasper, Jürgen; Mühlhauser, I; Nübling, M; Heesen, Christoph.
in: MULT SCLER J, Jahrgang 15, Nr. 1, 1, 2009, S. 96-104.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.
AU - Köpke, S
AU - Kasper, Jürgen
AU - Mühlhauser, I
AU - Nübling, M
AU - Heesen, Christoph
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Contrary to strong recommendations for high-dose intravenous corticosteroid treatment for relapses in multiple sclerosis (MS), uncertainty remains about most aspects of relapse management. Oral corticosteroids administered by physicians or patients themselves or no corticosteroids also appear justifiable. OBJECTIVE: To evaluate an education program that aims to involve patients with MS in decisions on relapse management. METHODS: In three German MS centers, 150 patients with relapsing MS were randomly assigned to a single, 4-h group session or a standard information leaflet. The primary outcome measure was the proportion of relapses with oral or no corticosteroid therapy as an indicator of patient autonomy in treatment decision making. Other outcomes included perceived decision autonomy, quality of life, and disability status. RESULTS: In the intervention group (IG), 108/139 (78%) relapses were treated with oral or no corticosteroids compared with 101/179 (56%) in the control group; P <0.0001. Patients' perceived autonomy of treatment decision making was significantly higher in the IG; P <0.0001. Quality of life, disability status, and adverse events of corticosteroid therapies were comparable. CONCLUSION: The patient education program led to more autonomous decision making in patients with relapsing MS. Relevant changes in relapse management were observed.
AB - BACKGROUND: Contrary to strong recommendations for high-dose intravenous corticosteroid treatment for relapses in multiple sclerosis (MS), uncertainty remains about most aspects of relapse management. Oral corticosteroids administered by physicians or patients themselves or no corticosteroids also appear justifiable. OBJECTIVE: To evaluate an education program that aims to involve patients with MS in decisions on relapse management. METHODS: In three German MS centers, 150 patients with relapsing MS were randomly assigned to a single, 4-h group session or a standard information leaflet. The primary outcome measure was the proportion of relapses with oral or no corticosteroid therapy as an indicator of patient autonomy in treatment decision making. Other outcomes included perceived decision autonomy, quality of life, and disability status. RESULTS: In the intervention group (IG), 108/139 (78%) relapses were treated with oral or no corticosteroids compared with 101/179 (56%) in the control group; P <0.0001. Patients' perceived autonomy of treatment decision making was significantly higher in the IG; P <0.0001. Quality of life, disability status, and adverse events of corticosteroid therapies were comparable. CONCLUSION: The patient education program led to more autonomous decision making in patients with relapsing MS. Relevant changes in relapse management were observed.
M3 - SCORING: Zeitschriftenaufsatz
VL - 15
SP - 96
EP - 104
JO - MULT SCLER J
JF - MULT SCLER J
SN - 1352-4585
IS - 1
M1 - 1
ER -
